WEKO3
アイテム
Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis
http://hdl.handle.net/2237/00030483
http://hdl.handle.net/2237/0003048399423296-95de-4576-830f-2f4d9f0de970
名前 / ファイル | ライセンス | アクション |
---|---|---|
IJRD_R1_Manuscript_clean_180718 (201.0 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-06-24 | |||||
タイトル | ||||||
タイトル | Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis | |||||
言語 | en | |||||
著者 |
Asai, Shuji
× Asai, Shuji× Nagai, Kaoru× Takahashi, Nobunori× Watanabe, Tatsuo× Matsumoto, Takuya× Asai, Nobuyuki× Sobue, Yasumori× Ishiguro, Naoki× Kojima, Toshihisa |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | This is the peer reviewed version of the following article: [Asai, S, Nagai, K, Takahashi, N, et al. Influence of methotrexate on gastrointestinal symptoms in patients with rheumatoid arthritis. Int J Rheum Dis. 2019; 22: 207– 213. https://doi.org/10.1111/apl.13380], which has been published in final form at [https://doi.org/10.1111/1756-185X.13380]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gastrointestinal symptoms | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | methotrexate | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | patient‐reported outcomes | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | quality of life | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | rheumatoid arthritis | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aim: This study aimed to determine the influence of methotrexate (MTX) on gastrointestinal (GI) symptoms in patients with rheumatoid arthritis (RA). Methods: This cross‐sectional study examined 529 consecutive patients with RA receiving oral MTX in our department between April 1 and September 30, 2017. GI symptoms were evaluated by the Gastrointestinal Symptom Rating Scale (GSRS); a score of ≥2 was considered “symptomatic.” Prevalence of GI symptoms was compared between patients receiving ≤8 mg/wk (low‐dose) vs >8 mg/wk (high‐dose) of MTX. Results: Of our study population, 313 (59%) received low‐dose MTX at a median (interquartile range) dose of 6 (6‐8) mg/wk, whereas 216 (41%) received high‐dose MTX at a median dose of 12 (10‐12) mg/wk. Relative to the low‐dose MTX group, the high‐dose MTX group exhibited a higher prevalence of reflux (32% vs 24%, P = 0.043) and abdominal pain (28% vs 18%, P = 0.007). There was no significant group‐dependent difference in the prevalence of indigestion, diarrhea or constipation. Multivariate logistic regression analysis revealed that high‐dose MTX (>8 mg/wk) was independently associated with reflux (odds ratio [OR]: 1.62, 95% confidence interval [CI]: 1.07‐2.43) and abdominal pain (OR: 1.60, 95% CI: 1.04‐2.43), and that the ORs for reflux and abdominal pain among those receiving high‐dose MTX (>8 mg/wk) were similar to those using nonsteroidal anti‐inflammatory drugs. Conclusion: High‐dose MTX is independently associated with the prevalence of upper GI symptoms in Japanese patients with RA. | |||||
言語 | en | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | ファイル公開:2020-02-01 | |||||
言語 | ja | |||||
出版者 | ||||||
出版者 | Wiley | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1111/1756-185X.13380 | |||||
ISSN(print) | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1756-1841 | |||||
書誌情報 |
en : International Journal of Rheumatic Diseases 巻 22, 号 2, p. 207-213, 発行日 2019-02 |
|||||
著者版フラグ | ||||||
値 | author |